Introduction {#Sec1}
============

Epigenetics describes biological phenomena resulting in heritable changes to gene expression that occur without alterations to the DNA sequence. Nearly all cells in the human body have the same genotype; however, during development they acquire a multitude of different phenotypes, resulting from differences in their gene expression patterns. Selective gene expression from the genome is shaped by epigenetic mechanisms and as a consequence cells vary from tissue to tissue in their epigenomes whilst the genome remains largely unchanged.

In eukaryotes, the majority of the DNA resides in the nucleus where it is packaged into a highly condensed structure called chromatin. The primary and repeating units of chromatin are the nucleosomes, which consist of 147 bp of DNA wrapped around an octamer of histone proteins formed by two copies of each of the core histones H2A, H2B, H3 and H4, with the linker histone H1 bound to the DNA between nucleosomes (reviewed in Luger et al. [@CR107]). Chromatin is dynamically and tightly regulated and many factors and mechanisms participate in this process (Fig. [1](#Fig1){ref-type="fig"}). These include the covalent modification of DNA and histone proteins, regulation of nucleosome assembly by histone chaperones, ATP-dependent remodeling of nucleosomes by chromatin remodeling factors to control DNA accessibility, and exchange of canonical histones against histone variants. These processes allow epigenetic information to be encoded in chromatin and together they act in regulating gene expression, DNA repair and replication.Fig. 1Mechanisms of chromatin regulation. Actively transcribed genes are found in open euchromatin and are associated with histone acetylation (*H3/H4Kac*) and tri-methylation of H3 lysine 4 (*H3K4me3*) at promotors, and tri-methylation of H3 lysine 36 (*H3K36me3*) over the gene body. Nucleosome positioning at promoters is regulated by ATP-dependent chromatin remodelers (*SWI/SNF*). Silenced genes are associated with densely packed heterochromatin marked by DNA methylation (*5mC*) and H3 lysine 9 tri-methylation (*H3K9me3*) or in silenced polycomb domains marked by tri-methylation of H3 lysine 27 (*H3K27me3*). Chromatin modifications are deposited by chromatin modifying enzymes such as DNA methyltransferases (*DNMTs*), histone acetyl transferases (*HATs*) or histone methyl transferases (*KMTs*) and removed by de-modifying enzymes such as histone deacetylases (*HDACs*) or histone demethylases (*KDMs*). These enzymes constitute intervention points for epigenetic therapies. A list of inhibitors against chromatin regulators is provided in Table [2](#Tab2){ref-type="table"}

The compaction of the genetic material into chromatin generally leads to repression of transcription, and genes and their regulatory regions need to be made accessible to transcription factors and chromatin associated proteins in order for gene expression to occur (Pazin et al. [@CR125]). The central importance of epigenetic mechanisms in establishing the correct gene expression programmes also means that pathological states may result if epigenetic regulation is compromised and the role of epigenetics in many diseases is now widely appreciated. The reversible nature of the underlying mechanisms, however, also provides plausible prevention and treatment options for diseases with epigenetic origins.

In this review, we will give an overview of the molecular lesions that can cause epigenetic diseases. These diseases are typically consequences of mutations in epigenetic regulators that are either inherited or acquired de novo, or originate from exposure to harmful environments (Fig. [2](#Fig2){ref-type="fig"}). We will focus on mechanisms directly related to chromatin regulation and we will discuss how diseases can arise when this regulation goes awry. We will concentrate on the three main mechanisms that govern chromatin regulation: DNA modification, histone post-translational modifications (PTMs) and chromatin remodeling, all of which play major roles in gene regulation and are implicated in the formation of a multitude of epigenetic diseases (Table [1](#Tab1){ref-type="table"}). A further important mechanism in controlling chromatin function is the exchange of canonical histones against histone variants. As there is little information concerning the role of histone variants in diseases beyond cancer, we will not further discuss them here; instead, we refer the reader to recent reviews summarizing our current knowledge for the field of cancer (Cantarino et al. [@CR22]; Vardabasso et al. [@CR171]).Fig. 2Chromatin deregulation in disease. Pathologies can result from changes in gene expression programmes caused by aberrant DNA methylation and histone modification patterns. These changes can be caused by environmental stresses that affect the chromatin state, deregulated expression of wild type (*WT*) chromatin regulators, or as a result of mutations (either inherited or acquired de novo) in genes encoding chromatin regulatory proteinsTable 1Diseases associated with chromatin deregulationDiseaseAffected GeneMechanismSymptomsOMIM reference^a^ReferencesDNA methylation Parkinson'sTNFA (TNF-alpha); SNCA (alpha-synuclein)Hypo-methylation at promoter regionsMuscular rigidity, tremors168600163890615869See review by Lu et al. ([@CR107]) Alzheimer'smanyLocus-specific hypo- or hyper methylationDementia and gradually worsening ability to form new memories104300 Huntington'sSCA7 locus; A2aRDNA methylation at CTCF binding sites (CAG repeats) at SCA7 locus, increased 5mC at A2aR promoterChorea, rigidity and dementia143100 Fragile X syndromeFMR1Hyper-methylation at CGG repeats repressing FMR1 expressionModerate to severe mental retardation, macroorchidism, and distinct facial features, including long face, large ears, and prominent jaw300624Jin and Warren ([@CR77]); Sutcliffe et al. ([@CR164]); Wang and Griffith ([@CR176]) Facioscapulohumeral muscular dystrophy (FSHD)FSHD locus 4q35Reduced DNA CpG methylation due to a reduction in number of D4Z4 repeatsProgressive wasting of facial, upper arm and shoulder girdle muscles158900Cabianca et al. ([@CR21]) Prader-Willi syndrome15q11-q13 locusImprintingInfantile hypotonia, obesity due to hyperphagia and mental retardation176270Cassidy and Schwartz ([@CR24]) Angelman syndromeUBE3A (E6AP)ImprintingSevere mental retardation105830Cassidy and Schwartz ([@CR24]); Kishino et al. ([@CR86]) Rett syndromeMECP2Reduced Methyl-DNA binding due to mutation in *MECP2*Mental retardation involving loss of acquired speech312750Amir et al. ([@CR5]); Bird ([@CR16]) Immunodeficiency, centromeric region instability, and facial anomalies syndrome (ICF)DNMT3BRearrangements and reduced CpG DNA methylation at satellite repeat regions on Chr 1, 9 and 16 due to mutation in DNMT3BFacial dysmorphism, immunoglobulin deficiency242860Ehrlich et al. ([@CR43]); Hansen et al. ([@CR62]); Xie et al. ([@CR188]); Xu et al. ([@CR189])Histone modifications Rubinstein--Taybi syndromeCREBBP (CBP, KAT3A); EP300 (KAT3B)Reduced HAT activity due to mutations in *CBP* and *EP300*Mental retardation, postnatal growth deficiency, microcephaly, broad thumbs and halluces, and dysmorphic facial features180849 613684Petrij et al. ([@CR128]); Roelfsema et al. ([@CR141]) Amyotrophic lateral sclerosis (ALS)FUS (TLS)Reduced HAT activity due to deregulation via FUSNeurodegenerative disorder characterised by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis105400 608030Janssen et al. ([@CR71]); Lazo-Gomez et al. ([@CR98]); Wang et al. ([@CR177]) Kleefstra syndromeEHMT1 (GLP, KMT1D)Reduced H3K9 MTase activity due to mutations in *EHMT1*Severe mental retardation, hypotonia, brachy(micro)cephaly, epileptic seizures, flat face with hypertelorism, synophrys, anteverted nares, everted lower lip, carp mouth with macroglossia, and heart defects610253Kleefstra et al. ([@CR87]) Weaver syndromeEZH2 (KMT6)Reduced H3K27me3 MTase activity due to mutations in *EZH2*Pre- and postnatal overgrowth, accelerated osseous maturation, characteristic craniofacial appearance, and developmental delay277590Gibson et al. ([@CR56]); Tatton-Brown et al. ([@CR168]); Tatton-Brown et al. ([@CR169]) Sotos syndromeNSD1 (KMT3B)Reduced H4K20 and H3K36 methylation due to mutations in *NSD1*Excessively rapid growth, acromegalic features, and a nonprogressive cerebral disorder with mental retardation117550Kurotaki et al. ([@CR94]) Kabuki syndromeMLL2 (KMT2B); UTX (KDM6A)De-regulated chromatin state due to mutations in one or both *MLL2* and *KDM6A*Mental retardation and postnatal dwarfism, a peculiar facies characterised by long palpebral fissures with eversion of the lateral third of the lower eyelids147920 300867Lederer et al. ([@CR100]); Miyake et al. ([@CR119]); Ng et al. ([@CR123]) X-linked mental retardationPHF8; JARID1C (SMCX, KDM5C)Reduced histone de-methylase activity due to mutations in *PHF8* and *JARID1C*Mental retardation, cleft lip and palate300263 300534Iwase et al. ([@CR70]); Jensen et al. ([@CR72]); Laumonnier et al. ([@CR95]) Brachydactyly mental retardation syndromeHDAC4Reduced HDAC activity due to haploinsufficiency of *HDAC4*Short stature, stocky build, mental retardation, brachymetaphalangia, and eczema600430Williams et al. ([@CR184])Chromatin remodeling CHARGE syndromeCHD7De-regulated chromatin state via CHD7 haploinsufficiencyColoboma, Heart malformations, Atresia of the choanae, Retardation of growth, Genital hypoplasia, and Ear abnormalities214800Vissers et al. ([@CR175]); Zentner et al. ([@CR197]) ATR-X syndrome; Juberg--Marsidi syndrome; Sutherland--Haan syndrome; Smith--Fineman--Myers syndromeATRX (RAD54L)De-regulated chromatin state via mutation in a SNF2-type helicaseα-Thalassemia, mental retardation, facial and skeletal abnormalities, urogenital abnormalities, microcephaly301040 309590 309470 309580Gibbons et al. ([@CR53]); Gibbons and Higgs ([@CR52]); Gibbons et al. ([@CR55]) Coffin-Siris syndrome; MRD12; MRD14; MRD15; MRD16SMARCB1 (BAF47, SNF5L1); SMARCA4 (BRG1, BAF190A, SNF2B); SMARCA2 (BRM, BAF190B, SNF2A); ARID1A (BAF250A); ARID1B (BAF250B)De-regulated chromatin state via mutations in SWI/SNF remodelersDevelopmental delay, intellectual disability, speech impairment, absent or hypoplastic fifth fingernails or toenails, hypotonia, hirsutism135900 614562 614607 614608 614609Tsurusaki et al. ([@CR171]) Cerebro-oculo-facio-skeletal syndrome (COFS); Cockayne syndromeERCC6 (CSB)De-regulated chromatin state via *ERCC6* mutationsPostnatal growth failure, neurological degeneration, cataracts, progressive joint contractures, dysmorphic features and premature death, UV sensitivity214150 133540Mallery et al. ([@CR111])A list of selected diseases associated with defects in chromatin regulation. The affected gene(s) and epigenetic mechanisms involved are described, as are the symptoms. Common synonyms for gene names are given in parentheses^a^Reference numbers for individual diseases can be found in the Online Mendelian Inheritance in Man catalogue: <http://www.ncbi.nlm.nih.gov/omim>

DNA modifications {#Sec2}
-----------------

The major form of DNA modification is methylation of the DNA at the 5-position of cytosine in CpG dinucleotides. The methyl mark is placed by enzymes known as DNA methyltransferases (DNMTs) that transfer a methyl group from S-adenosyl methionine to DNA (for a summary of the functions of DNA methylation and DNMTs see reviews by Li and Zhang [@CR103] and Jurkowska et al. [@CR82]). In mammals, DNA methyltransferases can be grouped into de novo DNMTs (DNMT3A and DNMT3B) and maintenance DNMTs (DNMT1). De novo DNMTs establish DNA methylation patterns during embryonic development and are highly expressed in embryonic stem (ES) cells and downregulated in differentiated tissues. The catalytically inactive DNMT3L acts as a general co-factor for DNMT3A and DNMT3B. DNMT1, on the other hand, has a preference for hemi-methylated DNA. It is thought to follow the replication fork via interactions with PCNA (Chuang et al. [@CR28]) and UHRF1 (Bostick et al. [@CR18]; Sharif et al. [@CR155]), in restoring DNA CpG methylation on the hemi-methylated DNA after synthesis of the daughter strand.

DNA methylation is generally associated with repressed regions of the genome. CpG dinucleotides constitute only around 1 % of the mammalian genome with the majority being methylated. CpG islands---regions of highly elevated CpG content---are associated with about 60 % of human gene promoters and are usually unmethylated in normal cells, although around 4 % become methylated in a tissue-specific manner during early development which generally leads to silencing of the associated genes (Borgel et al. [@CR17]; Shen et al. [@CR156]). However, gene body DNA methylation is coupled to transcriptional activation in ubiquitously expressed genes and might correlate with elongation efficiency (Laurent et al. [@CR95]; Lister et al. [@CR104]). Many repetitive elements present in the genome are silenced through DNA methylation to prevent aberrant expression that could cause chromosomal instability, translocations and gene disruption due to transposition events. DNA methylation is also involved in imprinting, which is the silencing of autosomal genes in a parent specific pattern. Imprinted genes tend to have a closely associated imprinting control region (ICR) the methylation status of which dictates whether the paternal or maternal allele is expressed (for a review of the mechanisms of imprinting see Sanli and Feil [@CR148]). A similar gene-dosage reduction is seen in X chromosome inactivation in females (for details see review by Chaligne and Heard [@CR26]). DNA methylation is further linked to nuclear organisation (reviewed in Pombo and Dillon [@CR131]), concentrating in dense silenced chromatin regions known as heterochromatin.

CpG methylation exerts its repressive effects by blocking DNA-binding proteins such as transcription factors from accessing DNA or by recruiting proteins that contain methyl-CpG binding domains (MBD). One example is MeCP2 which, in addition to its MBD, contains a transcriptional-repression domain (TRD) that recruits other co-repressors such as Sin3a and histone deacetylases as well as chromatin remodelers that maintain the silenced chromatin state (Jones et al. [@CR80]; Nan et al. [@CR120]).

DNA methylation has traditionally been regarded as a stable modification with few mechanisms for its removal. However, over recent years, oxidised forms of 5-methyl cytosine (5mC)---hydroxy-methyl cytosine, formyl-methyl cytosine, and carboxy-methyl cytosine---were identified (reviewed in Li and Zhang [@CR103]). The identification of these marks and the enzymes involved in their formation (such as the TET proteins) suggests that these oxidation products may form intermediates in the removal of the repressive 5mC mark. Furthermore, the oxidised forms of 5mC may also have independent roles in directly regulating gene expression (discussed in Wang et al. [@CR177]).

Histone modifications {#Sec3}
---------------------

Histone proteins are predominantly globular proteins with flexible N- and C-terminal tails that contain a high percentage of basic lysine and arginine residues protruding from the nucleosome particle. The amino acid residues on these flexible tails are extensively post-translationally modified. Numerous modifications exist such as lysine or arginine methylation, lysine acetylation and ubiquitylation, serine or threonine phosphorylation and ADP-ribosylation to name but a few. These PTMs rarely occur in isolation and it is the position, extent and context of the modifications that mediate their regulatory effects on chromatin (for a detailed review of histone modifications and their functions, see Bannister and Kouzarides [@CR9]).

Histone PTMs are deposited by modifying enzymes (collectively known as epigenetic "writers") such as methyltransferases (MTase) and acetyltransferases whilst de-modifying enzymes (or "erasers") remove these marks. These opposing activities enable a highly dynamic regulation of gene expression as modifications can be added or removed depending on whether a particular writer or eraser is recruited to a specific location of the genome. Histone PTMs act as docking sites for epigenetic "reader" proteins that contain modification-specific binding domains. These binding domains, such as bromodomains that can recognise acetylated lysines, or PHD domains that can bind methylated lysines, are integral in directing epigenetic effector proteins to chromatin (discussed in Yun et al. [@CR193]). Histone PTMs are thought to form a code that enables highly specific recruitment of epigenetic factors that mediate distinct downstream events to particular regions of chromatin (Jenuwein and Allis [@CR73]; Strahl and Allis [@CR162]). Histone modifications can also directly affect chromatin structure. Histone acetylation and phosphorylation effectively reduce the positive charge of histones and potentially affect the electrostatic interactions between histones and DNA or between neighbouring nucleosomes which can lead to a de-condensation of chromatin. This is supported by evidence that histone acetylation is associated with active open chromatin that is sensitive to DNase digestion (Hebbes et al. [@CR64]) and that acetylation of histone H4 at lysine 16 (H4K16) diminishes the compaction of chromatin arrays in vitro (Shogren-Knaak et al. [@CR159]).

Many histone PTMs correlate with gene expression (Fig. [1](#Fig1){ref-type="fig"}). For instance, lysine acetylation is generally associated with actively transcribed chromatin (termed euchromatin) along with methylation of histone H3 lysine 4, which marks promoter and enhancer regions, and H3K36 methylation that is found in active gene bodies. H3K9 and H3K27 methylation, on the other hand, are marks predominantly associated with silenced heterochromatic regions of the genome (Roadmap Epigenomics et al. [@CR137]).

Chromatin remodeling {#Sec4}
--------------------

A third mechanism involved in chromatin regulation is the control of nucleosome positioning by chromatin remodeling factors. Together with histone chaperones, chromatin remodelers shape chromatin architecture by relocating nucleosomes along the DNA, creating nucleosome free regions through eviction of histones, or by facilitating the deposition or exchange of new histones and histone variants. These factors allow access of the transcription machinery to the normally condensed genomic DNA and thereby control gene expression and processes such as DNA replication and repair. A common feature of all chromatin remodelers is the presence of an enzymatic ATPase subunit, which allows them to utilize the energy released from ATP hydrolysis to reposition nucleosomes. Chromatin remodelers are classified into four families (the SWI/SNF, ISWI, CHD and INO80/SWR1 families) based on their subunit composition and their modes of nucleosome remodeling. For further details regarding histone chaperones and chromatin remodelers, we refer the reader to two recent reviews (Gurard-Levin et al. [@CR60]; Narlikar et al. [@CR121]).

Deregulation of chromatin in disease {#Sec5}
====================================

Given the importance of chromatin modifications and nucleosome remodeling in gene regulation, it is apparent that loss or alteration of their functions can have detrimental consequences. Epigenetic deregulation has been the subject of an increasing number of studies into a wide range of pathologies from cancer to neurological disorders. Here, we will focus on the different mechanisms of chromatin regulation and discuss how defects in the epigenetic machinery can lead to disease (Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}).Fig. 3Factors involved in the formation of epigenetic diseases. Diseases caused by chromatin deregulation can arise through environmental stress, either during foetal development or later in life, or by mutations in genes encoding chromatin regulators. These mutations can be heritable or acquired de novo and can predispose an adult to disease in response to environmental stresses

Deregulated DNA methylation {#Sec6}
---------------------------

DNA methylation is generally associated with transcriptionally repressed chromatin. Various mechanisms can lead to DNA hypo- or hyper-methylation causing aberrant gene expression patterns underlying many diseases.

### Deregulated gene expression {#FPar1}

Several neurodegenerative disorders have been found to involve aberrant DNA methylation patterns at CpG-rich regions of disease-associated genes (discussed in Lu et al. [@CR106]).

In Parkinson's disease (PD), progressive loss of substantia nigra dopaminergic neurons and striatal projections causes muscular rigidity and tremors. Fibrillar aggregates of misfolded α-synuclein form Lewy bodies that accumulate at sites of neuronal loss. There is evidence for altered DNA methylation in the promoter of the *SNCA* gene (encoding α-synuclein) with decreased methylation in intron 1 that might lead to increased expression of α-synuclein and resulting formation of aggregates (Jowaed et al. [@CR81]). Methylation is generally reduced in the substantia nigra of PD patients resulting in an altered chromatin landscape (Matsumoto et al. [@CR112]). Further evidence indicates that DNMT1 expression is reduced in PD patient brains and in α-synuclein transgenic mice, with DNMT1 thought to be sequestered in the cytoplasm by α-synuclein, leading to hypo-methylated CpGs (Desplats et al. [@CR40]). Furthermore, hypo-methylation of the TNF-α gene promoter in the substantia nigra results in TNF-α overexpression and apoptosis of neuronal cells (Pieper et al. [@CR129]).

Aberrant DNA methylation patterns and mis-expression of disease-associated genes have also been found in other neurodegenerative disorders such as Alzheimer's and Huntington's disease and amyotrophic lateral sclerosis (see Lu et al. [@CR106]). An interesting aspect is that DNA methylation status could impact on the stability of CTG/CAG trinucleotide repeats and contribute to the expansion of the poly-glutamine stretch within the huntingtin protein that causes Huntington's disease (Behn-Krappa and Doerfler [@CR12]; Gorbunova et al. [@CR57]).

### Deregulated imprinting {#FPar2}

Aberrant methylation at ICRs of imprinted regions of the genome can lead to deregulated expression of imprinted genes. Two such diseases, Prader-Willi syndrome and Angelman syndrome, originate from a loss of regulation at the ICR at q11--q13 on chromosome 15 (see Cassidy and Schwartz [@CR24] and Clayton-Smith and Pembrey [@CR30]).

In Prader-Willi syndrome, loss of expression of several paternal genes in this region leads to infantile hypotonia, hyperphagia resulting in obesity, and mental retardation. Angelman syndrome on the other hand arises from the loss of maternally expressed genes in this region, specifically *UBE3A* (Kishino et al. [@CR85]; Matsuura et al. [@CR113]), leading to more severe mental retardation. Both are thought to involve cis-acting mutations preventing the re-setting of the imprinting signal specifically for this locus as other ICRs tend to be unaffected. In some cases of Angelman syndrome, MeCP2 mutations have been found, indicating a role for this methyl-CpG binding protein in imprinting at the 15q11 locus (Hogart et al. [@CR66]; Samaco et al. [@CR146]).

### Repeat expansion/deletion {#FPar3}

Genomic repeat sequences are generally methylated once above a threshold length to ensure transcriptional silencing. Repeats therefore tend to be located within heterochromatic regions. Some diseases arise from expansion or loss of repeats, leading to aberrant locus-specific CpG methylation that can affect gene expression of nearby genes.

Fragile X syndrome is caused by the silencing of the *FMR1* (Fragile X Mental Retardation 1) gene. An expansion of CGG tri-nucleotide repeats in the 5′UTR of *FMR1* has been associated with disease onset (Jin and Warren [@CR76]). Expansion to \>200 copies of this triplet repeat induces hyper-methylation in the *FMR1* promoter region and leads to transcriptional silencing (Sutcliffe et al. [@CR163]; Wang and Griffith [@CR175]). Examination of the genome-wide DNA methylation state indicates no other abnormally DNA methylated loci (Alisch et al. [@CR3]).

In a related mechanism, Facioscapulohumeral muscular dystrophy (FSHD) originates from a loss of repeats rather than repeat expansion. FSHD is an autosomal dominant disease that results in a progressive wasting of facial, upper arm and shoulder girdle muscles following the de-repression of genes at the *FSHD* locus in the sub-telomeric 4q35 region of chromosome 4. De-repression is caused by a reduced copy number of neighbouring D4Z4 repeats. A reduced number of repeats to \<11 leads to loss of polycomb-mediated repression and expression of a ncRNA called DBE-T that is located proximal to the D4Z4 repeats. DBE-T is produced only in FSHD patients and seems to act in a positive feedback loop to coordinate 4q35 de-repression by recruiting the tritorax group protein Ash1L. This ultimately results in the expression of neighbouring genes in the FSHD locus and onset of the disease (Cabianca et al. [@CR21]).

### Mutations in DNMTs {#FPar4}

The importance of DNA methylation suggests that defects in the machinery that deposit this modification will have deleterious consequences, and indeed DNMTs are found to be mutated in several diseases.

One example is ICF (immunodeficiency, centromere instability and facial anomalies) syndrome, a recessive autoimmune disease caused by a mutation in both alleles of *DNMT3B* (Hansen et al. [@CR62]; Xu et al. [@CR188]). Approximately 60 % of ICF patients have mutations in *DNMT3B* which is used in diagnosis of the disease. These mutations are usually missense mutations either in the catalytic domain (see Ehrlich et al. [@CR43]) or in the regions that mediate binding to DNMT3L, the non-active co-factor required for DNMT3B activity (Jiang et al. [@CR74]; Xie et al. [@CR187]). This results in a loss of catalytic activity but is not lethal, indicating that these mutations might alter the specificity of the enzyme so that it no longer recognises and methylates specific sequences whilst enabling other DNMT targets to remain unaffected. Indeed, HPLC analysis of the methylation level indicates only a 7 % hypo-methylation in the brain of ICF patients (Ehrlich [@CR42]).

ICF patients show DNA rearrangements targeted to juxtacentromeric heterochromatin regions of chromosomes 1, 9 and 16. These pericentromeric regions display marked DNA hypo-methylation in repeat sequences (satellite 2 and 3, alpha-satellite, Alu, D4Z4 and NBL2 repeats), as observed in lymphocytes, that is thought to result in the instability of this constitutive heterochromatin (Ehrlich et al. [@CR43]). Despite generally unchanged global DNA methylation levels there are some changes to expression of genes involved in immune response function and neurodevelopment. The direct causal effect of this is not fully understood but changes observed in ICF patients include CpG hypo-methylation at DNMT3B target genes, and loss of the repressive tri-methyl H3K27 (H3K27me3) and gain of the activating H3K4me3 mark (Jin et al. [@CR77]).

### Mutations in methyl-CpG binding proteins {#FPar5}

The ability to recognise methylated regions of the genome is important for establishing transcriptional repression in response to DNA methylation.

The major factor involved is methyl-CpG-binding protein MeCP2 that binds methylated DNA through its MBD domain (see Bird [@CR16]). Mutations in *MECP2* cause Rett syndrome, a form of postnatal mental retardation involving the regression from relatively normal cognitive function to a loss of speech and motor skills within the first few years of childhood (Amir et al. [@CR5]). It is an X-linked neurological disease affecting almost exclusively females where patients tend to be heterozygous for the mutated allele (random X inactivation results in a mosaic phenotype in females). The mutated allele is almost exclusively acquired de novo in the germ cells with mutations varying from single missense mutations to truncated or mis-folded versions of the protein. Missense mutations frequently occur within the MBD region, thus preventing the protein from binding methylated DNA. Other mutations also target the TRD domain that is involved in binding and recruiting co-repressors such as Sin3a and HDAC1 (Lyst et al. [@CR108]). The resulting loss of repression of methylated genomic regions directly contributes to disease onset.

Knockout mouse models for *MECP2* have confirmed the cause and phenotype for Rett syndrome (Chen et al. [@CR27]; Collins et al. [@CR32]). However, there is striking evidence that these defects could be reversible. The lack of neuronal cell death suggests that Rett syndrome is a neurodevelopmental disease rather than being neurodegenerative and it was hypothesised that adding back functional MeCP2 may rescue the phenotype. Restoration of the gene was indeed found to rectify *MECP2* KO mice indicating a principle of reversibility for neurodevelopmental disorders (Bird [@CR16]; Cobb et al. [@CR31]; Guy et al. [@CR61])

Deregulated histone modifications {#Sec7}
---------------------------------

A major mechanism in the epigenetic regulation of chromatin is the post-translational modification of histone proteins. Mutation or deregulated expression of histone modifying or de-modifying enzymes can lead to altered deposition of modification marks. As discussed above, loss in the regulatory control of histone modifications has the potential to affect gene expression and can directly impact on chromatin structure. Histone modifiers can induce global changes in gene expression patterns in response to upstream signals. Therefore, perturbations in their ability to process these signals can have knock-on effects in gene regulatory networks.

### Aberrant histone acetylation {#FPar6}

A histone mark associated with active gene expression is lysine acetylation. Acetyl groups are transferred to lysines by histone acetyltransferases (HATs) and removed by histone de-acetylases (HDACs) (for details see Bannister and Kouzarides [@CR9]). Neurodegenerative and other neurological disorders are generally characterised by histone hypo-acetylation due to reduced HAT activity or increased HDAC activity.

Rubinstein--Taybi syndrome is an example of an autosomal dominant disorder resulting in cognitive dysfunction that is associated with loss of HAT activity (Petrij et al. [@CR127]). It is a genetically heterogeneous disease, with 55 % of patients displaying mutations in the *CBP* (CREB binding protein) and 3 % in the *EP300* gene whereas the remainder are uncharacterised (Roelfsema et al. [@CR140]). CBP and p300 are both HATs with co-activator function in gene expression. Heterozygous *CBP*^*+/−*^ mice display a reduction in H2B acetylation by more than 30 % and failure in long-term memory function mirroring the symptoms of Rubinstein--Taybi syndrome (Alarcon et al. [@CR2]).

Another pathology involving deregulated histone acetylation is amyotrophic lateral sclerosis (ALS). This is a fatal neurodegenerative disease resulting from the death of upper and lower motor neurons. Familial ALS stems from mutations in *SOD1* (superoxide dismutase) but this only accounts for approximately 10 % of patients whereas sporadic ALS is vastly uncharacterised (see Lazo-Gomez et al. [@CR97]). A major cause of the disease appears to be the formation of cytoplasmic aggregates of mis-folded FUS protein. FUS is an RNA-binding protein with roles in splicing, nuclear transport and translation but it might also have a role in transcription (Ishigaki et al. [@CR69]; Schwartz et al. [@CR153]). FUS binds CBP, strongly inhibiting HAT activity and negatively regulates CREB target genes (Wang et al. [@CR176]). Furthermore, there is an alteration in HDAC levels in the brain and spinal cord of ALS patients with decreased HDAC1 and increased HDAC2 mRNA levels (Janssen et al. [@CR71]). This indicates that aberrant histone acetylation seems to play a role in ALS.

### Aberrant histone methylation {#FPar7}

Lysine and arginine methylation of histones is another important mechanism in chromatin regulation and several diseases have been associated with aberrant histone methylation patterns.

Kleefstra syndrome is associated with haplo-insufficiency of the histone MTase EHMT1 that deposits H3K9me2 marks (Kleefstra et al. [@CR86]; Ogawa et al. [@CR123]). Its symptoms include intellectual disability and muscular hypotonia. Mutations involve a range of deletions, from large to very small, in the *EHMT1* locus leading to a loss of its MTase activity. Indeed, in mouse models the loss of *EHMT1* results in reduced learning and memory, hypotonia and cranial abnormalities (Balemans et al. [@CR8]; Schaefer et al. [@CR151]). EHMT1 was found to interact with several transcriptional repressors, including E2F6 and REST. Loss of targeted H3K9-methylation may therefore be important for disease onset (Ogawa et al. [@CR123]; Roopra et al. [@CR142]; Tahiliani et al. [@CR165]).

Other diseases caused by loss of histone MTase activity are Weaver and Sotos syndrome (Tatton-Brown et al. [@CR168]). Both are mostly sporadic diseases and have similar traits, including intellectual disability and tall stature but interestingly see mutations in alternative MTase enzymes. Weaver syndrome displays mutations in the *EZH2* gene, the MTase subunit of the PRC2 complex, that primarily cluster to the catalytic SET domain and result in reduced H3K27me3 levels (Gibson et al. [@CR56]; Tatton-Brown et al. [@CR167]). In Sotos syndrome, however, mutations primarily affect *NSD1* (Kurotaki et al. [@CR93]) which is thought to abrogate methylation of H3K36 as well as H4K20 (Rayasam et al. [@CR135]). The similar phenotypes indicate a common pathway between these two seemingly separate chromatin modifiers.

A similar situation is found in Kabuki syndrome, which can result from loss-of function mutations in either the H3K4 MTase MLL2 or the H3K27 de-methylase KDM6A (Lederer et al. [@CR99]; Miyake et al. [@CR118]; Ng et al. [@CR122]). In both cases, mutations presumably lead to reduced active marks and increased repressive marks in the diseased state, possibly causing reduced gene expression at common target loci since MLL2 and KDM6a have been show to reside in the same protein complex.

### Aberrant histone de-modifiers {#FPar8}

Apart from KDM6A there are examples of several other histone de-modifying enzymes being associated with mental retardation syndromes (discussed in Kramer and van Bokhoven [@CR90]).

PHF8 is a H3K9 de-methylase that binds to tri-methylated H3K4 and localises to transcription start sites. Mutations in its de-methylase domain have been associated with X-linked mental retardation (XLMR) (Laumonnier et al. [@CR94]). PHF8 interacts with zinc-finger protein ZNF711 (Kleine-Kohlbrecher et al. [@CR87]), another XLMR protein, and both proteins share common target genes including *KDM5C* (also known as SMCX or JARID1C). KDM5C is a H3K4 de-methylase that binds methylated H3K9 through a PHD domain and missense mutations in *KDM5C* itself have been associated with XLMR (Iwase et al. [@CR70]; Jensen et al. [@CR72]). XLMR exemplifies that, although individual epigenetic effectors have specific functions, the overriding effect on gene expression programmes is dictated by the interplay between several readers, writers and erasers and upsetting this balance can lead to disease.

Deregulation of HDACs is known to contribute to cancer formation, but HDAC mutations are also linked to other diseases. *HDAC4* haplo-insufficiency has been linked to brachydactyly mental retardation syndrome, causing developmental delays, behavioural problems and sleep disturbance, and craniofacial and skeletal abnormalities (Williams et al. [@CR183]). This disease is caused by deletions at the 2q37.3 locus (a region encoding *HDAC4*) or de novo mutations of *HDAC4* in the germ line that result in reduced HDAC activity.

Deregulation of chromatin remodeling {#Sec8}
------------------------------------

In recent years, several complex disease syndromes have been linked to mutations in genes encoding chromatin remodeling enzymes. Prominent examples are ATRX syndrome, α-thalassemia, Sutherland--Haan syndrome, Juberg--Marsidi and Smith--Fineman--Myers syndrome all of which are caused by mutations in the *ATRX* gene. All syndromes share common phenotypes including mental retardation, mild α-thalassemia and facial, skeletal and urogenital abnormalities during development (discussed in Gibbons and Higgs [@CR52]). The ATRX mutations concentrate in two conserved domains, the ADD and the helicase domains (Gibbons et al. [@CR55]). Although the precise disease mechanisms are still unknown, all disorders display changes in methylation patterns at DNA repeats (Gibbons et al. [@CR54]). *ATRX* encodes an ATP-dependent type II helicase of the SNF2 family that is highly expressed during development. ATRX primarily localises to pericentromeric heterochromatin, rDNA repeats, telomeres and PML bodies (Gibbons et al. [@CR54]; McDowell et al. [@CR115]; Xue et al. [@CR189]). It associates with two key heterochromatin proteins, HP1 (Lechner et al. [@CR98]) and EZH2 (Cardoso et al. [@CR23]), and co-operates with the histone chaperone DAXX to deposit H3.3 into chromatin (Lewis et al. [@CR101]; Xue et al. [@CR189]). ATRX appears to recruit methyltransferases to repetitive heterochromatic sequences possibly through binding to transcribed repeat RNAs (Sarma et al. [@CR150]). Further studies showed an association with G-rich tandem repeats linking it to the potential recognition of G-quadruplex structures in vivo, which are prevalently found in telomeres (Law et al. [@CR96]). Indeed, loss of ATRX causes telomere instability. The notion that ATRX plays a role at telomeres is also supported by the finding that it concentrates at late replicating chromatin and that loss of ATRX causes delays in completing DNA replication (Huh et al. [@CR67]). The exact molecular mechanisms and the link between the various observed abnormalities caused by ATRX mutations remain to be established.

A second example of a disease involving defective chromatin remodeling is CHARGE syndrome, which is caused by heterozygous mutations in the gene encoding CHD7 (Vissers et al. [@CR174]). CHARGE syndrome is characterised by developmental retardation with specific heart defects, genital hypoplasia, vestibular disorders, ear abnormalities and deafness. The molecular causes underlying the disorder are not yet understood and the disease is associated with many phenotypes with the clinical variability between patients and even between family members carrying the same mutations being very broad (Zentner et al. [@CR196]). Several CHD7 mutations identified in CHARGE syndrome were found to affect its nucleosome remodeling activity (Bouazoune and Kingston [@CR19]). CHD7 recognises all methylated forms of histone H3K4 and localises to regions of active transcription and enhancer elements (Schnetz et al. [@CR152]). The binding pattern and the functionality of the protein suggest that CHD7 promotes transcription by binding enhancer elements and transiently looping chromatin to transcription start sites.

Extrinsic and intrinsic factors influencing the epigenome {#Sec9}
=========================================================

The main cause for the diseases discussed above are genetic mutations that lead to detrimental changes in the chromatin landscape. The plasticity of the epigenome also means that it can respond to stimuli from the environment that affect transcriptional regulation without changes in the DNA sequence. Exposure to environmental stresses and cross-talk/feedback between the epigenetic machinery and the environment can reinforce faulty gene expression patters leading to disease (Fig. [3](#Fig3){ref-type="fig"}).

The nature versus nurture conundrum has sparked studies attempting to understand how the environment influences the susceptibility, progression and outcome of diseases. Research in the human population focuses on monozygotic twins, a fortunate model for genetically identical individuals that show significantly different gene-expression phenotypes and often different susceptibilities to diseases such as mental disorders, diabetes, obesity, allergies and longevity. It has been demonstrated that twins vary in their epigenomes (Fraga et al. [@CR49]). The Epitwin project ([http://www.epitwin.eu](http://www.epitwin.eu/)) plans to trace differences in the methylation patterns of 20 million CpG islands in 5000 monozygotic twins with the goal of explaining why twins do not develop the same diseases and how the epigenome responds to external stimuli.

Intrinsic factors {#Sec10}
-----------------

Genetic mutations in chromatin regulators are the major causes of epigenetic diseases. They can either be inherited (as seen in hereditary diseases) or occur de novo in the germline of the parents, during embryogenesis or somatically (Fig. [3](#Fig3){ref-type="fig"}). Apart from genetic factors, there also appear to exist naturally occurring processes that perturb chromatin modification patterns without altering the DNA sequence.

After each cell division, the DNA methylation pattern is passed on to the daughter cells, a process safeguarded by DNMTs. Strikingly, global methylation levels tend to decrease in many tissues with increasing age. This large-scale hypomethylation appears to be stochastic and mainly localised to repetitive sequences such as SINEs and LTRs possibly leading to genomic instability (Berdasco and Esteller [@CR13]; Ronn et al. [@CR141]; Wilson and Jones [@CR184]; Zampieri et al. [@CR195]). In addition, there are reports of ageing-related hyper-methylation events. These are relatively sparse and mostly targeted to specific CpG island promoters resulting in silencing of associated genes (discussed in Zampieri et al. [@CR195]). The hypo- and hyper-methylation events observed during ageing resemble methylation patterns seen in cancer and could promote oncogenesis by silencing tumour suppressors or predispose aged individuals to other age-related diseases. For example, in Alzheimer's disease amyloid-β protein deposition in the brain has been connected with cytosine de-methylation at the *APP* gene leading to its increased expression (Tohgi et al. [@CR169]), and the COX7A1 gene, which plays a role in glucose metabolism was found to become highly methylated with age (Ronn et al. [@CR141]). This might increase the risk of insulin resistance and contribute to the development of type-2 diabetes commonly affecting elderly individuals.

Interestingly, levels of histone modifications were also found to be deregulated with age, and in the premature ageing disease Hutchinson--Gilford Progeria Syndrome the deregulation of histone modifications recapitulates some of the epigenetic alterations observed in normal ageing. Specifically, there is a reduction of H3K9me3 and H3K27me3 paralleled with a downregulation of EZH2, and a spread of H4K20me3 (see Prokocimer et al. [@CR132]).

Influence of the environment {#Sec11}
----------------------------

### Cigarette smoking {#FPar9}

Exposure to cigarette smoke has been correlated with an increased risk of epigenetic diseases. Cigarettes contain more than 500 chemicals, and when smoked 4,000 chemicals are produced. Many of these have been linked to development of emphysema, heart diseases and cancer. Promoter hyper-methylation of tumour-suppressor genes was demonstrated in non-tumourigenic lung tissues of smokers, but not in the corresponding tissue of non-smokers (Zochbauer-Muller et al. [@CR197]). Shenker et al. ([@CR157]) also identified hypo-methylated loci associated with smokers compared to former and non-smokers (Shenker et al. [@CR157]). The effect of smoking on DNA methylation varies between ethnic groups due to different genetic and environmental backgrounds causing different susceptibility to diseases. For example, the DNA methylation level of the lung cancer-associated *AHRR* locus was lower for European smokers than for South Asian smokers (Elliott et al. [@CR44]).

### Nutrition {#FPar10}

The link between nutrition and epigenetics is exceptionally important as nutrients and bioactive food components directly influence epigenetic events and impact on gene expression at the transcription level (discussed in Jimenez-Chillaron et al. [@CR75]). Nutrients such as vitamin B-12, choline, folate and methionine affect histone and DNA methylation through their involvement in 1-carbon metabolism and were shown to be capable of increasing DNA methylation levels at specific loci in animal models (Waterland [@CR178]) and humans (Waterland et al. [@CR179]). Histone acetylation is linked to energy metabolism and responds to intracellular glucose levels through the availability of the HAT co-factor acetyl coenzyme A (Takahashi et al. [@CR166]; Wellen et al. [@CR181]). Oncogenic Kras and Akt signaling were shown to cause increased histone acetylation in tumours through stimulation of ATP-citrate lyase, the key enzyme for cytoplasmic acetyl coenzyme A synthesis (Lee et al. [@CR100]). Substances occurring in some foods, like butyrate in cheeses, diallyl disulphide in garlic and sulphoraphane in broccoli, are natural HDAC inhibitors. Therefore, these substances have been proposed in cancer chemoprevention as possible mediators for induction of apoptosis by increasing acetylation and de-repressing genes such as *P21* and *BAX* (discussed in Dashwood and Ho [@CR34]).

In development, critical epigenetic events occur at specific time windows during which the entire epigenome is reprogrammed and post-translational marks are erased and then re-established. Nutrition was shown to influence the epigenome during embryonic development and early childhood with potential pathologies later in life (see review by Jimenez-Chillaron et al. [@CR75]). Maternal nutritional status and particular diets can affect chromatin structure in embryonic tissues depending on the developmental stage. In the case of foetal starvation, there is high correlation with type-2 diabetes susceptibility in adulthood (Park et al. [@CR124]; Sandovici et al. [@CR147]). If the epigenome of developing germ cells is affected, these conditions can also be passed on between generations. Recent mouse studies demonstrate that the in utero nutritional environment of embryos during development alters the germline DNA methylome of adult males in a locus-specific manner. Although the differential methylation pattern is not maintained in the tissues of the following generations, perturbed locus-specific gene expression persists (Radford et al. [@CR133]).

### Developmental stress {#FPar11}

Stress exposure in early life (ELS) has been associated with higher risk of mental pathologies such as bipolar disorder, schizophrenia, depression, anxiety and posttraumatic stress disorder (discussed in Gershon et al. [@CR51]). The effects of poor maternal care on offspring at an epigenetic level have been studied in mouse models, showing that gene expression and methylation levels are affected in pups and that the phenotype can be rescued when the same pups are fostered by caring mothers (Francis et al. [@CR50]). Genes that regulate the hypothalamic pituitary adrenal axis, which is functionally responsible for the homeostatic response during stress, were found to be deregulated at an epigenetic level in animals and humans affected by ELS. Specifically, the expression levels of neurotrophic factor BDNF were reported to be lower in ELS mouse models (Roth et al. [@CR143]) and in patients affected by mental disorders and exposed to childhood trauma (Ernst et al. [@CR45]; Hashimoto et al. [@CR63]). This coincides with increased methylation levels at the BDNF locus and its receptor TrkB (Perroud et al. [@CR126]). In addition, hyper-methylation of the NR3C1 gene was found in ELS animal models and in adults with childhood trauma. This was reversed by changing the fostering of the pups and by the use of HDAC inhibitors (Weaver et al. [@CR180]) underscoring the value of drugs targeting reversible epigenetic events (see below).

### Environmental factors {#FPar12}

Chemicals and pollutants found in the environment have been associated with epigenetic pathologies. Heavy metal ions such as cadmium, chromium and nickel (Salnikow and Costa [@CR145]; Shiao et al. [@CR158]) were found to reduce methylation levels at genetic loci by inhibiting the activity of DNMTs (Poirier and Vlasova [@CR130]). In addition, compounds that until recently were designated for different usage such as diethylstilbestrol (Veurink et al. [@CR173]), a drug previously used to prevent miscarriages, bisphenol A (Maffini et al. [@CR109]), used in the plastics industry, and vinclozolin (Anway et al. [@CR6]), a fungicide used in vineyards, were found to be endocrine disruptors and have been convincingly related to altered DNA methylation at specific promoters, developmental disorders and tumourigenesis.

Epigenetic deregulation in complex diseases {#Sec12}
===========================================

Given the enormous importance of epigenetic modifications for gene regulation, development and tissue homeostasis, it is not surprising that disruption of epigenetic mechanisms causes pathologies affecting various tissues and organs. Certain diseases originate from mutation or deregulation of several genes, often in combination with environmental factors. Recent technological developments have enabled the large scale sequencing of patient genomes and have linked mutations in epigenetic regulators to multifactorial diseases such as congenital heart diseases, mental disorders and cancer. Patients with polygenic diseases often display alterations in common pathways mostly caused by de novo mutations in functionally related genes.

Sequencing of patients with congenital heart defects has revealed an extensive list of mutations in H3K4 methylation regulators including MLL2, KDM6A, KDM5A, KDM5B, CHD7 and WDR5 (Zaidi et al. [@CR194]). Mutations in MLL2 and KDM6A are also implicated in Kabuki syndrome (Lederer et al. [@CR99]; Miyake et al. [@CR118]; Ng et al. [@CR122]), whilst mutations in CHD7 are implicated in CHARGE syndrome (Vissers et al. [@CR174]). Both diseases have heart defects as common symptoms.

De novo mutations in CHD8 and other chromatin remodelers including CHD7 have been associated with Autism Spectrum Disorders (ASD), neurodevelopmental disorders that affect social interaction, communication and behaviour (summarised in Krumm et al. [@CR91]). Interestingly, CHD8 interacts with CHD7 (Batsukh et al. [@CR11]) and the majority of CHARGE syndrome patients suffer from ASD (Johansson et al. [@CR78]), demonstrating that mutations in related epigenetic pathways can result in different syndromes with shared symptoms depending on the context and nature of a particular mutation.

Cancer has traditionally been regarded as being mainly caused by genetic defects. However, over the last two decades, the role of epigenetic deregulation as a hallmark of cancer has been widely acknowledged. Genome-wide hypo-methylation is commonly observed in cancer (Feinberg and Vogelstein [@CR46]) and has been linked to chromosomal instability (Eden et al. [@CR41]). Epigentic silencing by de novo promoter methylation has been recognised as an additional pathway in Knudson's two hit hypothesis postulating that two events are necessary for the inactivation of a tumour suppressor. Clear examples of this are the de novo methylation of gene promoters for the *Rb, CDKN2A* (p16^INKa^) and *CDKN2B* (p15^INKb^) tumour suppressors (see Jones and Laird [@CR79]). Mutations in coding sequences of epigenetic regulators are also often found in tumours, e.g. the DNA-modifying enzymes DNMT3A and TET2 are frequently mutated in leukaemia, lymphomas and myeloid cancers (Delhommeau et al. [@CR38]; Ley et al. [@CR102]). Furthermore, histone modifying enzymes such as HATs and histone MTases or de-modifying enzymes such as HDACs and histone de-methylases are deregulated in cancer. Observed lesions include missense mutations, truncations, deletions and amplifications leading to altered expression levels, and---especially for the H3K4 methyltransferase MLL and the HATs p300 and CBP---the expression of fusion proteins resulting from chromosomal translocations (see Dawson and Kouzarides [@CR35]). In addition, chromatin remodelers have been implicated in cancer (discussed in Wilson and Roberts [@CR185]). The first link between chromatin remodeling and cancer emanated from the discovery that SNF5 (*SMARCB1/BAF47*), a subunit of the human SWI/SNF remodeling complex, is inactivated in rhabdoid tumours (Biegel et al. [@CR15]; Versteege et al. [@CR172]). Homozygous *SNF5* deficiency results in embryonic lethality in mice whereas heterozygous loss predisposes to aggressive cancers, similar to those seen in humans (Guidi et al. [@CR59]; Klochendler-Yeivin et al. [@CR88]; Roberts et al. [@CR138]). The mechanisms behind this have not been fully elucidated but given the central role for SWI/SNF in regulating nucleosome positioning it is not surprising that SWI/SNF components are mutated in 20 % of all human cancers (see Kim and Roberts [@CR84]). Components of the SWI/SNF complex are also implicated in Coffin--Siris syndrome (Tsurusaki et al. [@CR170]), again demonstrating that the outcome of particular mutations is context dependent.

Advances in high-throughput sequencing have also enabled mapping of mutations that are associated with cancer, which can help in identifying targets for diagnosis and treatment (Simo-Riudalbas and Esteller [@CR160]). For example, pan-sequencing efforts have identified recurrent mutations in previously unknown chromatin genes such as *ASXL1* (Abdel-Wahab et al. [@CR1]; Inoue et al. [@CR68]), where mutations have been implicated in the loss of PRC2-mediated methylation of H3K27 leading to myeloid transformation. In addition, global DNA hypo-methylation and locus specific hyper-methylation in tumours allows DNA methylation signatures to be used as potential biomarkers in cancer diagnosis and prognosis (Fernandez et al. [@CR47]). The promoter methylation level of the O^6^--methguanine-DNA methyltransferase (*MGMT*) gene, which encodes a DNA repair enzyme that protects cells against alkylating agents, has been shown to be a suitable marker for early detection of drug resistance. Hyper-methylation of the promoter correlates with good response of patients to alkylating antineoplastic drugs such as temozolomide (Wick et al. [@CR182]). Changes in histone modification levels have also been used as prognostic markers. For example, lower levels of H3K4me2, H3K18ac and H3K9me2 are associated with poorer outcomes in lung and kidney cancer (Seligson et al. [@CR154]). The ongoing improvements in epigenetic profiling techniques promise to rationalise the treatment of diseases in which epigenetic pathways are deregulated.

Epigenetic therapies {#Sec13}
====================

The reversibility of epigenetic events makes the epigenetic machinery an attractive target for therapeutic intervention. A high number of drugs targeting epigenetic factors and/or pathways are currently being developed or tested in clinical trials (discussed in Heerboth et al. [@CR65]). Amongst them are histone methyltransferase and de-methylase inhibitors (see McGrath and Trojer [@CR116]) and BET inhibitors (reviewed in Barbieri et al. [@CR10]), a class of drugs that compete for binding of BET proteins (bromodomain and extra terminal family proteins) to acetylated histones and cause the downregulation of c-myc in myc-dependent cancers. The majority of drugs currently approved for clinical use target DNA methylation and histone acetylation levels by inhibiting the DNMTs and HDACs (Table [2](#Tab2){ref-type="table"}).Table 2Epigenetic drugsDrug classDrugTargetReferenceDNA methylation inhibitorsNucleoside analogues5-azacytidine (Vidaza)^a^DNMT1Cataldo et al. ([@CR25])5-aza-2′-deoxycytidine (Decitabine)^a^DNMT1Saba ([@CR144])ZebularineDNMT1Yoo et al. ([@CR192])5-fluoro-2′-deoxycytidineDNMT1Beumer et al. ([@CR14])S110DNMT1Chuang et al. ([@CR29])Antisense oligonucleotideMG98DNMT1Amato et al. ([@CR4])Small molecule inhibitorRG108DNMT1Graca et al. ([@CR58])HDAC inhibitorsHydroxamic acidsSuberoylanilide hydroxamic acid (Vorinostat)^a^HDACsMann et al. ([@CR111])Panabinostat^a^HDACsRichardson et al. ([@CR136])Belinostat^a^HDACsRashidi and Cashen ([@CR134])DepsipeptidesRomidepsin (Istodax)^a^HDACsYazbeck and Grant ([@CR191])Short-chain fatty acidsValproic acid (Depakene)^a^HDACsPhiel et al. ([@CR128])Benzamide derivativesMS-275 (Entinostat)^a^HDACsSee review by De Souza and Chatterji ([@CR37])ITF-2357 (Givinostat)HDACsMGCD-0103 (Mocetinostat)HDACsPCI-24781 (Abexinostat)HDACsBromodomain inhibitorsSmall molecule inhibitorsJQ1BET family proteinsDelmore et al. ([@CR39]); Filippakopoulos et al. ([@CR48])I-BET151BET family proteinsDawson et al. ([@CR36])I-BET726BET family proteinsWyce et al. ([@CR186])HAT inhibitorsSmall molecule inhibitorC646p300 (KAT3B)Bowers et al. ([@CR20])Histone methyltransferase inhibitorsSmall molecule inhibitorsEPZ-5676DOT1L (KMT4)Daigle et al. ([@CR33])EPZ-6438EZH2 (KMT6)Knutson et al. ([@CR89])GSK126EZH2 (KMT6)McCabe et al. ([@CR114])3-deazaneplanocin A (DZNep)H3K27me3 and H4K20me3Miranda et al. ([@CR117])BIX-01294EHMT1/2 (GLP/G9A; KMT1D/C)Kubicek et al. ([@CR92])UNC0642EHMT1/2 (GLP/G9A; KMT1D/C)Liu et al. ([@CR105])A-366EHMT1/2 (GLP/G9A; KMT1D/C)Sweis et al. ([@CR164])Histone de-methylase inhibitorsTranylcyprominesORY-1001LSD1 (KDM1A)See review by McGrath and Trojer ([@CR116])GSK2879552LSD1 (KDM1A)A list of drugs targeting chromatin regulators commonly associated with diseaseCommon synonyms for gene names are given in parentheses. For a more exhaustive overview of compounds targeting epigenetic regulators we refer the reader to several recent reviews (McGrath and Trojer [@CR116]; Rodriguez-Paredes and Esteller [@CR139]; Yang et al. [@CR190])^a^Drugs approved for clinical use by the US Food and Drug Administration (FDA)

Nucleoside-mimicking drugs were shown to have anti-proliferative properties. 5-Azacytidine (Aza; commercially: Vidaza), a cytidine analogue in which nitrogen replaces the carbon 5 atom, was the first to be used in clinical applications. Aza intercalates into DNA during replication. DNMT1 recognises the nucleotide analogue and irreversibly links to the nitrogen resulting in DNMT1 degradation and therefore reduction of methylation in dividing cells (Kaminskas et al. [@CR83]; Momparler [@CR119]; Santi et al. [@CR149]). More recently, less toxic and more stable analogues (e.g. Zebularine, 5-fluoro-2-deoxycytidine, S110) have been developed and are in clinical trials. Other DNMT1 inhibitors such as RG108 and the antisense oligonucleotide MG98 that blocks translation of the DNMT1 mRNA are also being tested as inhibitors of DNA methylation.

A second class of drugs that have been approved for clinical use are histone deacetylase inhibitors (HDACi). HDACs are linked to chromatin silencing and their inhibition is thought to promote the reactivation of inappropriately silenced genes such as tumour suppressors. HDAC inhibitors belong to different structural classes such as epoxyketones, benzamides and short chains fatty acids. Valproic acid (a fatty acid HDACi) functions as a competitive binder to acetyl groups on the N-terminal histone tails by blocking the catalytic site of HDACs. It is currently being used for treating mental disorders such as epilepsy and bipolar disorders and is in clinical trials for cancer (see Slingerland et al. [@CR161]). SAHA, also known as Vorinostat, is an anti T cell lymphoma drug that acts as a chelator for zinc ions found in the active site of HDACs. It causes histone, p53 and Hsp90 hyper-acetylation leading to apoptosis of cancer cells and sensitisation of tumours to other antineoplastic drugs. SAHA is also being investigated as an anti-HIV drug (Archin et al. [@CR7]). In addition to these clinically approved drugs, a large number of novel molecules targeting a variety of epigenetic regulators are currently under development or in clinical trials (Table [2](#Tab2){ref-type="table"}) providing an exciting outlook for epigenetic therapies.

Conclusions {#Sec14}
===========

The epigenetic regulation of chromatin affects many fundamental biological pathways, from basic DNA transactions such as transcription, replication and DNA repair, to the establishment and maintenance of cell identity during development and tissue homeostasis. Many diseases are caused by mutations in chromatin regulators. These are typically monogenic diseases with mutations inherited from the parents, acquired de novo in the parental germline or in somatic tissues, or complex polygenic diseases. Environmental insults resulting from malnutrition, stress or exposure to harmful chemicals can also have considerable impact on the epigenome. The realisation that deregulation of chromatin causes or contributes to the formation of diseases has sparked significant efforts to develop epigenetic therapies. Changes in gene expression resulting from aberrant epigenetic regulation are potentially reversible and drugs targeting the epigenetic machinery have proven effective in the treatment of various diseases. However, since chromatin regulators are expressed in many tissues and are critical for many basic biological processes, a disadvantage of epigenetic drugs to date is their broad specificity and potentially adverse side effects. The rapid developments in high throughput sequencing technologies are enabling the profiling of individual genomes and epigenomes. These signatures can be valuable biomarkers in disease diagnosis and prognosis, and to devise effective avenues for therapeutic intervention. The ongoing development of drugs with improved characteristics and genomic and epigenomic profiling promise to catalyse personalised treatment strategies that will allow effective use of epigenetic drugs alongside other drugs in combination therapies tailored to a patient's condition.
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